Answers are grounded in this paper and cite their sources.
We report a patient with multiple myeloma who was treated with pamidronate disodium every 3 weeks for 18 months without any other chemotherapeutic agents. Pamnidronate therapy resulted in a marked reduction of marrow plasmacytosis and serum paraprotein levels, and recovery from anemia together with an increase in bone mineral density (BMD). To our knowledge, this is only the third report in which bisphosphonates showed anti-myeloma effects in humans and the result suggests that the compound has a clinically useful anti-tumor effect.
No takes yet. Share an insight, caveat, or question.
Kondo et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: